GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » Shiller PE Ratio

Aravive (Aravive) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aravive Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aravive Shiller PE Ratio Historical Data

The historical data trend for Aravive's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Shiller PE Ratio Chart

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aravive's Shiller PE Ratio

For the Biotechnology subindustry, Aravive's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aravive's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aravive's Shiller PE Ratio falls into.



Aravive Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aravive's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Aravive's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.28/129.8595*129.8595
=0.280

Current CPI (Sep. 2023) = 129.8595.

Aravive Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -1.499 98.326 -1.980
201403 -96.780 99.695 -126.063
201406 -2.160 100.560 -2.789
201409 -3.420 100.428 -4.422
201412 -3.900 99.070 -5.112
201503 -4.740 99.621 -6.179
201506 -4.020 100.684 -5.185
201509 -4.140 100.392 -5.355
201512 -4.140 99.792 -5.387
201603 -4.920 100.470 -6.359
201606 -4.500 101.688 -5.747
201609 -5.520 101.861 -7.037
201612 -3.840 101.863 -4.895
201703 -5.100 102.862 -6.439
201706 -6.240 103.349 -7.841
201709 -8.370 104.136 -10.438
201712 5.220 104.011 6.517
201803 -1.500 105.290 -1.850
201806 -1.640 106.317 -2.003
201809 -1.080 106.507 -1.317
201812 -4.820 105.998 -5.905
201903 -0.420 107.251 -0.509
201906 -0.270 108.070 -0.324
201909 -0.540 108.329 -0.647
201912 -0.350 108.420 -0.419
202003 -0.720 108.902 -0.859
202006 -0.320 108.767 -0.382
202009 -0.660 109.815 -0.780
202012 -0.250 109.897 -0.295
202103 -0.440 111.754 -0.511
202106 -0.350 114.631 -0.396
202109 -0.530 115.734 -0.595
202112 -0.620 117.630 -0.684
202203 -0.620 121.301 -0.664
202206 -0.610 125.017 -0.634
202209 -0.510 125.227 -0.529
202212 -0.460 125.222 -0.477
202303 -0.660 127.348 -0.673
202306 -0.120 128.729 -0.121
202309 0.280 129.860 0.280

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aravive  (NAS:ARAV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aravive Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aravive's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (Aravive) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Executives
Maria Carolina Petrini officer: Chief Commercial Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard officer: Chief Financial Officer 322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove officer: Chief Operating Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia director, 10 percent owner C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre officer: Chief Scientific Officer C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk director 225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc director 319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani director, officer: President and CEO 3928 POINT EDEN WAY, HAYWARD CA 94545

Aravive (Aravive) Headlines